<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28177189</article-id><article-id pub-id-type="pmc">5484992</article-id><article-id pub-id-type="doi">10.1111/dom.12899</article-id><article-id pub-id-type="publisher-id">DOM12899</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Acute physiological effects of glucocorticoids on fuel metabolism in humans are permissive but not direct</article-title><alt-title alt-title-type="right-running-head"><styled-content style="fixed-case">STIMSON</styled-content> et al.</alt-title><alt-title alt-title-type="left-running-head"><styled-content style="fixed-case">STIMSON</styled-content> et al.</alt-title></title-group><contrib-group><contrib id="dom12899-cr-0001" contrib-type="author" corresp="yes"><name><surname>Stimson</surname><given-names>Roland H.</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9002-6188</contrib-id><address><email>roland.stimson@ed.ac.uk</email></address><xref ref-type="aff" rid="dom12899-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12899-cr-0002" contrib-type="author"><name><surname>Anderson</surname><given-names>Anna J.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom12899-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12899-cr-0003" contrib-type="author"><name><surname>Ramage</surname><given-names>Lynne E.</given-names></name><degrees>BSc</degrees><xref ref-type="aff" rid="dom12899-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12899-cr-0004" contrib-type="author"><name><surname>Macfarlane</surname><given-names>David P.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom12899-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12899-cr-0005" contrib-type="author"><name><surname>de Beaux</surname><given-names>Andrew C.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12899-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12899-cr-0006" contrib-type="author"><name><surname>Mole</surname><given-names>Damian J.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom12899-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="dom12899-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom12899-cr-0007" contrib-type="author"><name><surname>Andrew</surname><given-names>Ruth</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom12899-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12899-cr-0008" contrib-type="author"><name><surname>Walker</surname><given-names>Brian R.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12899-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="dom12899-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Centre for Cardiovascular Science, Queen's Medical Research Institute</named-content><institution>University of Edinburgh</institution><named-content content-type="city">Edinburgh</named-content><country country="GB">UK</country></aff><aff id="dom12899-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Department of Upper GI Surgery</named-content><institution>Royal Infirmary of Edinburgh</institution><named-content content-type="city">Edinburgh</named-content><country country="GB">UK</country></aff><aff id="dom12899-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">MRC Centre for Inflammation Research</named-content><institution>Queen's Medical Research Institute, University of Edinburgh</institution><named-content content-type="city">Edinburgh</named-content><country country="GB">UK</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold> Roland H. Stimson PhD, C3.03, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK. Email: <email>roland.stimson@ed.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2017</year></pub-date><volume>19</volume><issue>6</issue><issue-id pub-id-type="doi">10.1111/dom.2017.19.issue-6</issue-id><fpage>883</fpage><lpage>891</lpage><history><date date-type="received"><day>03</day><month>11</month><year>2016</year></date><date date-type="rev-recd"><day>23</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>03</day><month>2</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>Diabetes, Obesity and Metabolism</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-19-883.pdf"/><abstract><sec id="dom12899-sec-0001"><title>Background and aims</title><p>The effects of glucocorticoids on fuel metabolism are complex. Acute glucocorticoid excess promotes lipolysis but chronic glucocorticoid excess causes visceral fat accumulation. We hypothesized that interactions between cortisol and insulin and adrenaline account for these conflicting results. We tested the effect of cortisol on lipolysis and glucose production with and without insulin and adrenaline in humans both <styled-content style="italic-in-any-context">in vivo</styled-content> and <styled-content style="italic-in-any-context">in vitro</styled-content>.</p></sec><sec id="dom12899-sec-0002"><title>Materials and methods</title><p>A total of 20 healthy men were randomized to low and high insulin groups (both n&#x02009;=&#x02009;10). Subjects attended on 3 occasions and received low (c. 150&#x02009;n<styled-content style="fixed-case">M</styled-content>), medium (c. 400&#x02009;n<styled-content style="fixed-case">M</styled-content>) or high (c. 1400&#x02009;n<styled-content style="fixed-case">M</styled-content>) cortisol infusion in a randomized crossover design. Deuterated glucose and glycerol were infused intravenously along with a pancreatic clamp (somatostatin with replacement of glucagon, insulin and growth hormone) and adrenaline. Subcutaneous adipose tissue was obtained for analysis. In parallel, the effect of cortisol on lipolysis was tested in paired primary cultures of human subcutaneous and visceral adipocytes.</p></sec><sec id="dom12899-sec-0003"><title>Results</title><p>
<styled-content style="italic-in-any-context">In vivo</styled-content>, high cortisol increased lipolysis only in the presence of high insulin and/or adrenaline but did not alter glucose kinetics. High cortisol increased adipose <styled-content style="fixed-case">mRNA</styled-content> levels of <styled-content style="fixed-case">ATGL</styled-content>, <styled-content style="fixed-case">HSL</styled-content> and <styled-content style="fixed-case">CGI</styled-content>&#x02010;58 and suppressed <styled-content style="italic-in-any-context"><styled-content style="fixed-case">G0S2</styled-content></styled-content>. <styled-content style="italic-in-any-context">In vitro</styled-content>, high cortisol increased lipolysis in the presence of insulin in subcutaneous, but not visceral, adipocytes.</p></sec><sec id="dom12899-sec-0004"><title>Conclusions</title><p>The acute lipolytic effects of cortisol require supraphysiological concentrations, are dependent on insulin and adrenaline and are observed only in subcutaneous adipose tissue. The resistance of visceral adipose tissue to cortisol's lipolytic effects may contribute to the central fat accumulation observed with chronic glucocorticoid excess.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12899-kwd-0001">adipose tissue</kwd><kwd id="dom12899-kwd-0002">adrenaline</kwd><kwd id="dom12899-kwd-0003">body composition</kwd><kwd id="dom12899-kwd-0004">drug mechanism</kwd><kwd id="dom12899-kwd-0005">glucocorticoid</kwd><kwd id="dom12899-kwd-0006">glucose</kwd><kwd id="dom12899-kwd-0007">insulin resistance</kwd><kwd id="dom12899-kwd-0008">metabolism</kwd></kwd-group><funding-group><award-group><funding-source>Medical Research Council, Academy of Medical Sciences/Wellcome Trust</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Edinburgh and Lothians Health Foundation and the British Heart Foundation</funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="1"/><page-count count="1"/><word-count count="6414"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12899</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.2 mode:remove_FC converted:27.06.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="dom12902-cit-0000">
<string-name>
<surname>Stimson</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Ramage</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Macfarlane</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>de Beaux</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Mole</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Andrew</surname>
<given-names>R</given-names>
</string-name> and <string-name>
<surname>Walker</surname>
<given-names>BR</given-names>
</string-name>. <article-title>Acute physiological effects of glucocorticoids on fuel metabolism in humans are permissive but not direct</article-title>, <source>Diabetes Obes Metab</source>, <year>2017</year>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/dom.12899">https://doi.org/10.1111/dom.12899</ext-link>
</mixed-citation>
</p></notes><notes><fn-group id="dom12899-ntgp-0002a"><fn id="dom12899-note-0002a"><p>
<bold>Funding information</bold> This work was funded by the Medical Research Council, Academy of Medical Sciences/Wellcome Trust, the Edinburgh and Lothians Health Foundation and the British Heart Foundation.</p></fn></fn-group></notes></front><body><sec id="dom12899-sec-0005"><label>1</label><title>INTRODUCTION</title><p>Glucocorticoids are critical regulators of energy balance; however, their complex effects on fuel metabolism are highly context&#x02010;dependent, are not linear in their dose response and are influenced by factors such as the diurnal rhythm.<xref rid="dom12899-bib-0001" ref-type="ref">1</xref> One area exemplifying this lack of certainty is the effects of glucocorticoids on adipose tissue.<xref rid="dom12899-bib-0002" ref-type="ref">2</xref> The prevailing belief is that, in times of acute stress, high cortisol concentrations promote lipolysis to provide adequate energy substrate for utilization by the body. However, chronically elevated cortisol concentrations, most commonly resulting from iatrogenic glucocorticoid administration to treat inflammatory diseases or, alternatively, because of ACTH&#x02010; or cortisol&#x02010;secreting tumours, leads to weight gain and, in particular, accumulation of visceral adipose tissue.<xref rid="dom12899-bib-0003" ref-type="ref">3</xref> The reasons for these 2 apparently conflicting observations are unclear. Several studies have examined the effects of glucocorticoids on lipolysis; however, results have been inconsistent. For example, <italic>in vitro</italic> studies in adipocytes have shown lipolytic rates to be increased,<xref rid="dom12899-bib-0004" ref-type="ref">4</xref> unchanged<xref rid="dom12899-bib-0005" ref-type="ref">5</xref> or decreased<xref rid="dom12899-bib-0006" ref-type="ref">6</xref> by glucocorticoids. These discrepancies may be attributed to several factors, including the dose and duration of glucocorticoid treatment, the effect of other hormones in the media and the species being studied.</p><p>Results from <italic>in vivo</italic> studies testing the effect of glucocorticoids on lipolysis have been more consistent, particularly when levels of other counter&#x02010;regulatory hormones have been clamped by infusing somatostatin and replacing insulin, growth hormone and glucagon (the pancreatic clamp technique), showing that cortisol acutely increases whole body lipolysis.<xref rid="dom12899-bib-0007" ref-type="ref">7</xref>, <xref rid="dom12899-bib-0008" ref-type="ref">8</xref>, <xref rid="dom12899-bib-0009" ref-type="ref">9</xref> However, these studies achieved cortisol concentrations between 850 and 1500&#x02009;nM which are not reflective of those observed physiologically in the absence of acute stress. Two studies have examined the effect of physiological cortisol concentrations on <italic>in vivo</italic> lipolysis and had conflicting results in the fasted state;<xref rid="dom12899-bib-0001" ref-type="ref">1</xref>, <xref rid="dom12899-bib-0010" ref-type="ref">10</xref> however, neither study used a pancreatic clamp to control counter&#x02010;regulatory hormones. Therefore, it is unclear whether changes in cortisol concentrations within the physiological range alter whole body lipolysis. It is also unclear how glucocorticoids enhance lipolysis in humans, as no <italic>in vivo</italic> study has examined the effect of glucocorticoids on the lipolytic pathway (Figure <xref rid="dom12899-supitem-0001" ref-type="supplementary-material">S1</xref>, Supporting Information).</p><p>Over and above prevailing glucocorticoid concentrations, a further critical confounder is the effect of other hormones regulating lipolysis, notably insulin and adrenaline.<xref rid="dom12899-bib-0005" ref-type="ref">5</xref>, <xref rid="dom12899-bib-0006" ref-type="ref">6</xref>
<italic>In vivo</italic>, the effect of interactions between cortisol and either adrenaline<xref rid="dom12899-bib-0011" ref-type="ref">11</xref> or insulin<xref rid="dom12899-bib-0012" ref-type="ref">12</xref> has been examined only once in humans, although systemic rates of lipolysis were not measured as the appropriate tracers were not infused. We hypothesized that the effects of glucocorticoids on lipolysis in humans are indirect and dependent on the prevailing insulin and/or adrenaline concentrations, with glucocorticoids augmenting the pro&#x02010;lipolytic effects of adrenaline and antagonizing the suppressive effects of insulin. In addition, we hypothesized that these interactions may account for the apparently contradictory effects of acute (a state of high adrenaline and low insulin) and chronic (a state of high insulin and low adrenaline) glucocorticoid excess and that the effects may differ between subcutaneous and visceral depots. To test this, we performed a randomized, double&#x02010;blinded, crossover study to determine the effects of glucocorticoids on whole body lipolysis in the presence of both low and high insulin and adrenaline, respectively. Furthermore, we collected adipose tissue biopsies <italic>in vivo</italic> to determine how glucocorticoids alter lipolysis and tested <italic>in vitro</italic> whether glucocorticoids have differential effects on lipolysis in subcutaneous and visceral adipocytes.</p></sec><sec id="dom12899-sec-0006"><label>2</label><title>MATERIALS AND METHODS</title><sec id="dom12899-sec-0007"><label>2.1</label><title>
<styled-content style="italic-in-any-context">In vivo</styled-content> protocol</title><p>A total of 20 healthy men were recruited to a randomized, double&#x02010;blind, placebo&#x02010;controlled crossover study with the following inclusion criteria: age, 18 to 75&#x02009;years; body mass index, 20 to 25&#x02009;kg/m<sup>2</sup>; absence of chronic medical conditions; absence of regular medications; no previous glucocorticoid use in the past year; alcohol intake &#x02264;21 units per week; weight change of &#x0003c;5% over the past 6&#x02009;months; normal screening blood tests (renal, liver and thyroid function, fasting glucose, full blood count). Local ethical approval was obtained, as was written informed consent from each participant.</p><p>Subjects attended the Edinburgh Clinical Research Facility after overnight fast on 3 occasions, each separated by 3&#x02009;weeks, and were instructed to avoid alcohol and exercise for 48&#x02009;hours prior to each assessment. Volunteers were randomized to low, medium or high glucocorticoid (GC) phases (Figure <xref rid="dom12899-supitem-0001" ref-type="supplementary-material">S2</xref>, Supporting Information). The night prior to each assessment (11&#x02009;<sc>pm</sc>) subjects received orally the 11&#x003b2;&#x02010;hydroxylase inhibitor metyrapone (metopirone) 1&#x02009;g, along with either placebo (low GC phase), hydrocortisone 10&#x02009;mg (medium GC) or hydrocortisone 20&#x02009;mg (high GC). At 7&#x02009;<sc>am</sc> the following morning subjects received orally 1&#x02009;g of metyrapone along with either placebo (low GC), hydrocortisone 5&#x02009;mg (medium GC) or hydrocortisone 10&#x02009;mg (high GC). A further 1&#x02009;g of metyrapone was received orally at 11&#x02009;<sc>am</sc> to maintain inhibition of endogenous cortisol synthesis throughout the protocol. The 3 GC phases aimed to achieve trough and peak cortisol concentrations observed during normal diurnal rhythm (low and medium GC, respectively) and peak cortisol concentrations during stress (high GC).</p><p>At each visit, measurements were performed of height, weight, blood pressure, body fat by bioimpedance (using an Omron BF&#x02010;302 analyser) and core body temperature using a tympanic thermometer. Three cannulae were inserted (1 in a vein in each ante&#x02010;cubital fossa for infusions and 1 retrograde in a dorsal hand vein for arterialised sampling). Subjects placed their hand in a box heated to 60&#x000b0;C for 5&#x02009;minutes prior to each arterialized sample collection. At t&#x02009;=&#x02009;0&#x02009;minutes, intravenous infusions of 6,6&#x02010;[<sup>2</sup>H]<sub>2</sub>&#x02010;glucose (at 0.22&#x02009;&#x000b5;mol/kg/min following a 17.6&#x02009;&#x000b5;mol/kg bolus) and 1,1,2,3,3&#x02010;[<sup>2</sup>H]<sub>5</sub>&#x02010;glycerol (at 0.11&#x02009;&#x000b5;mol/kg/min following a 1.6&#x02009;&#x000b5;mol/kg bolus) were commenced for 6.5&#x02009;hours (Figure <xref rid="dom12899-supitem-0001" ref-type="supplementary-material">S2</xref>, Supporting Information). A &#x0201c;pancreatic clamp&#x0201d; was commenced at t&#x02009;=&#x02009;0&#x02009;minutes, comprising intravenous somatostatin (60&#x02009;ng/kg/min), glucagon (0.5&#x02009;ng/kg/min) and growth hormone (2&#x02009;ng/kg/min). At their first visit, subjects were further randomized to receive either low or high insulin replacement (both groups n&#x02009;=&#x02009;10) at a rate of 0.06&#x02009;mU/kg/min or 0.2&#x02009;mU/kg/min (aiming to suppress lipolysis by c. 50%),<xref rid="dom12899-bib-0013" ref-type="ref">13</xref> respectively, and subjects remained in this group for all 3 study visits. At t&#x02009;=&#x02009;0&#x02009;minutes, subjects commenced infusion with 0.9% saline (low GC) or hydrocortisone (medium GC at 0.025&#x02009;mg/kg/h following a 0.04&#x02009;mg/kg bolus; high GC at 0.12&#x02009;mg/kg/h following a 0.18&#x02009;mg/kg bolus) in random order. At t&#x02009;+&#x02009;20&#x02009;minutes, an intravenous infusion of 20% dextrose was commenced and the rate was adjusted every 10&#x02009;minutes to maintain an arterialized glucose concentration between 7.5 and 8.0&#x02009;mmol/L. Steady state measurements were taken between t&#x02009;+&#x02009;180 and t&#x02009;+&#x02009;240&#x02009;minutes; following this a subcutaneous abdominal adipose tissue biopsy was obtained by needle aspiration.<xref rid="dom12899-bib-0014" ref-type="ref">14</xref> At t&#x02009;+&#x02009;285&#x02009;minutes, an adrenaline infusion was commenced at 0.15&#x02009;nmol/kg/min for 60&#x02009;minutes. Blood samples were obtained at regular intervals (Figure <xref rid="dom12899-fig-0001" ref-type="fig">1</xref>). Samples were stored at &#x02212;80&#x000b0;C until analysis.</p><fig fig-type="Figure" xml:lang="en" id="dom12899-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Hormone and metabolite concentrations during infusions. Data are given as mean&#x02009;&#x000b1;&#x02009;<styled-content style="fixed-case">SEM</styled-content> for n&#x02009;=&#x02009;10 for low glucocorticoid (<styled-content style="fixed-case">GC</styled-content>) (squares), medium <styled-content style="fixed-case">GC</styled-content> (circles) and high <styled-content style="fixed-case">GC</styled-content> (triangles) in low insulin (dotted lines, open shapes) and high insulin (solid lines, filled shapes) groups. <styled-content style="fixed-case">A</styled-content>, <styled-content style="fixed-case">P</styled-content>lasma cortisol was different between all 3 <styled-content style="fixed-case">GC</styled-content> phases (<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.001). <styled-content style="fixed-case">B</styled-content>, <styled-content style="fixed-case">S</styled-content>erum insulin was increased in the high insulin group (<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.01) but unchanged by <styled-content style="fixed-case">GC</styled-content> phase. <styled-content style="fixed-case">C</styled-content>, <styled-content style="fixed-case">G</styled-content>lucose; <styled-content style="fixed-case">D</styled-content>, growth hormone; <styled-content style="fixed-case">E</styled-content>, adrenaline; <styled-content style="fixed-case">F</styled-content>, glucagon were unchanged by <styled-content style="fixed-case">GC</styled-content> phase or between insulin groups. <styled-content style="fixed-case">ADR</styled-content>, adrenaline infusion</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-19-883-g001"/></fig></sec><sec id="dom12899-sec-0008"><label>2.2</label><title>
<styled-content style="italic-in-any-context">In vitro</styled-content> protocol</title><p>Paired samples of subcutaneous and visceral adipose tissue were obtained from patients undergoing elective abdominal surgery at the Royal Infirmary of Edinburgh (subject characteristics detailed in Table <xref rid="dom12899-supitem-0001" ref-type="supplementary-material">S1</xref>, Supporting Information). Adipose tissue from subcutaneous and visceral depots was digested, and the stromal vascular fraction was isolated and differentiated as previously described.<xref rid="dom12899-bib-0015" ref-type="ref">15</xref> In brief, following removal of connective tissue and blood vessels, adipose tissue was digested in collagenase type 1 (615&#x02009;units/g tissue) for 90&#x02009;minutes at 37&#x000b0;C. Following plating and overnight incubation in DMEM/F12 medium containing 33&#x02009;&#x003bc;M biotin, 17&#x02009;&#x003bc;M pantothenate and 10% foetal bovine serum, cells were differentiated for 3&#x02009;days using serum&#x02010;free medium plus 1&#x02009;nM triiodothyronine, 10&#x02009;&#x000b5;g/mL transferrin, 66&#x02009;nM insulin, 500&#x02009;&#x003bc;M isobutylmethylxanthine, 1&#x02009;&#x003bc;M dexamethasone and 10&#x02009;&#x003bc;M rosiglitazone. From day 4 onwards, cells were maintained in differentiation medium, but without isobutylmethylxanthine, dexamethasone or rosiglitazone.</p><p>On day 16, cells were incubated with either 0, 100 or 1000&#x02009;nM cortisol for 24&#x02009;hours in the presence or absence of either vehicle, 100&#x02009;pM insulin or 10&#x02009;&#x003bc;M adrenaline. Following incubation, cells were used to measure mRNA levels of key genes in the lipolytic pathway or the medium was removed to measure the appearance of glycerol and cells were lysed and stored at &#x02212;80&#x000b0;C for quantification of total protein.</p></sec><sec id="dom12899-sec-0009"><label>2.3</label><title>Laboratory analyses</title><sec id="dom12899-sec-0010"><label>2.3.1</label><title>Biochemical measurements</title><p>Serum lipids were measured on an Olympus Diagnostics analyser (County Clare, Ireland) using an enzymatic colorimetric method. Serum insulin, growth hormone, plasma glucagon and cortisol were measured by RIA kits (MP Biomedicals, Santa Ana, California). Serum non&#x02010;esterified fatty acids (NEFAs) were measured using a colorimetric assay (Wako Diagnostics, Mountain View, California) and plasma adrenaline by ELISA (Rocky Mountain Diagnostics, Colorado Springs, Colorado).</p><p>Endogenous and tracer glucose and glycerol concentrations <italic>in vivo</italic> were measured by GC&#x02010;MS as previously described.<xref rid="dom12899-bib-0016" ref-type="ref">16</xref> Glycerol in cell medium was measured in duplicate using a colorimetric kit (Sigma, Poole, UK). Protein in cell lysates was measured in duplicate using the DC protein assay (Bio&#x02010;Rad, Hercules, California) and glycerol appearance corrected for total protein.</p></sec><sec id="dom12899-sec-0011"><label>2.3.2</label><title>Quantitative real time <styled-content style="fixed-case">PCR</styled-content> measurements</title><p>qPCR in whole adipose tissue and cultured adipocytes was performed as previously described.<xref rid="dom12899-bib-0017" ref-type="ref">17</xref> Primer sequences and probe numbers are described in Table <xref rid="dom12899-supitem-0001" ref-type="supplementary-material">S2</xref>, Supporting Information. Transcript levels are presented as the ratio of the abundance of the gene of interest: mean of abundance of control genes encoding cyclophilin A and 18S.</p></sec></sec><sec id="dom12899-sec-0012"><label>2.4</label><title>Kinetic analysis</title><p>Kinetic analysis for steady state (ss) measurements was performed using the mean of 5 samples obtained from t&#x02009;+&#x02009;180 to t&#x02009;+&#x02009;240&#x02009;minutes. Steele's steady state equation<xref rid="dom12899-bib-0018" ref-type="ref">18</xref> was used to measure the rate of appearance (Ra) of glycerol as shown in Equation <xref rid="dom12899-disp-0001" ref-type="disp-formula">1</xref>, where d5&#x02010;Glycerol TTR<sub>ss</sub> is the tracer/tracee ratio (eg, d5&#x02010;Glycerol/Glycerol) during steady state:<disp-formula id="dom12899-disp-0001"><label>(1)</label><mml:math id="nlm-math-1"><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mspace width="0.25em"/><mml:mtext>Glycero</mml:mtext><mml:msub><mml:mi mathvariant="normal">l</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="sans-serif">d</mml:mi><mml:mn mathvariant="sans-serif">5</mml:mn><mml:mo>&#x02010;</mml:mo><mml:mtext mathvariant="normal">Glycerol &#x02009;infusion &#x02009;rate</mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">d</mml:mi><mml:mn mathvariant="sans-serif">5</mml:mn><mml:mo>&#x02010;</mml:mo><mml:mtext mathvariant="normal">Glycerol</mml:mtext><mml:mspace width="0.37em"/><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">T</mml:mi><mml:msub><mml:mi mathvariant="normal">R</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula>
</p><p>The rate of disposal (Rd) of glucose was similarly calculated using Equation <xref rid="dom12899-disp-0002" ref-type="disp-formula">2</xref> while Ra glucose<sub>ss</sub> was calculated by subtracting the mean of the glucose infusion rate (GIR<sub>ss</sub>) during steady state from Rd glucose<sub>ss</sub>:<disp-formula id="dom12899-disp-0002"><label>(2)</label><mml:math id="nlm-math-2"><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mspace width="0.25em"/><mml:mtext>Glucos</mml:mtext><mml:msub><mml:mi mathvariant="normal">e</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="sans-serif">d</mml:mi><mml:mn mathvariant="sans-serif">2</mml:mn><mml:mo>&#x02010;</mml:mo><mml:mtext>Glucose</mml:mtext><mml:mspace width="0.37em"/><mml:mtext mathvariant="normal">infusion &#x02009;rate</mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">d</mml:mi><mml:mn mathvariant="sans-serif">2</mml:mn><mml:mo>&#x02010;</mml:mo><mml:mtext>Glucose</mml:mtext><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">T</mml:mi><mml:msub><mml:mi mathvariant="normal">R</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula>
<disp-formula id="dom12899-disp-0003"><label>(3)</label><mml:math id="nlm-math-3"><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mspace width="0.25em"/><mml:mtext>Glucos</mml:mtext><mml:msub><mml:mi mathvariant="normal">e</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mo>=</mml:mo><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="sans-serif">d</mml:mi><mml:mspace width="0.25em"/><mml:mtext>Glucos</mml:mtext><mml:msub><mml:mi mathvariant="normal">e</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mspace width="0.25em"/><mml:mi mathvariant="sans-serif">G</mml:mi><mml:mi mathvariant="sans-serif">I</mml:mi><mml:msub><mml:mi mathvariant="sans-serif">R</mml:mi><mml:mrow><mml:mi mathvariant="sans-serif">s</mml:mi><mml:mi mathvariant="sans-serif">s</mml:mi></mml:mrow></mml:msub></mml:math></disp-formula>
</p><p>Kinetic analysis following commencement of the adrenaline infusion was performed using Steele's modified non&#x02010;steady state equations.<xref rid="dom12899-bib-0018" ref-type="ref">18</xref> Ra glycerol and Rd glycerol were calculated as follows, where pV is volume of distribution:
<disp-formula id="dom12899-disp-0004"><label>(4)</label><mml:math id="nlm-math-4"><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mspace width="0.25em"/><mml:mtext>Glycero</mml:mtext><mml:msub><mml:mi mathvariant="normal">l</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="sans-serif">d</mml:mi><mml:mn mathvariant="sans-serif">5</mml:mn><mml:mo>&#x02010;</mml:mo><mml:mtext mathvariant="normal">Glycerol infusion rate</mml:mtext><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="sans-serif">p</mml:mi><mml:mi mathvariant="sans-serif">V</mml:mi><mml:mspace width="0.25em"/><mml:mo>&#x000d7;</mml:mo><mml:mfrac><mml:mrow><mml:mfenced open="[" close="]"><mml:mrow><mml:mtext mathvariant="normal">Glycero</mml:mtext><mml:msub><mml:mi mathvariant="sans-serif">l</mml:mi><mml:mrow><mml:mi mathvariant="sans-serif">t</mml:mi><mml:mn mathvariant="sans-serif">1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced open="[" close="]"><mml:mrow><mml:mtext mathvariant="normal">Glycero</mml:mtext><mml:msub><mml:mi mathvariant="sans-serif">l</mml:mi><mml:mrow><mml:mi mathvariant="sans-serif">t</mml:mi><mml:mn mathvariant="sans-serif">2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mo>&#x000d7;</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mn mathvariant="normal">5</mml:mn><mml:mo>&#x02010;</mml:mo><mml:mi mathvariant="normal">Glycerol</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="sans-serif">T</mml:mi><mml:mi mathvariant="normal">T</mml:mi><mml:msub><mml:mi mathvariant="sans-serif">R</mml:mi><mml:mrow><mml:mi mathvariant="sans-serif">t</mml:mi><mml:mn mathvariant="sans-serif">2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="normal">d</mml:mi><mml:mn>5</mml:mn><mml:mo>&#x02010;</mml:mo><mml:mtext mathvariant="normal">Glycerol</mml:mtext><mml:mspace width="0.25em"/><mml:mi mathvariant="sans-serif">T</mml:mi><mml:mi mathvariant="sans-serif">T</mml:mi><mml:msub><mml:mi mathvariant="sans-serif">R</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mn mathvariant="sans-serif">1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="sans-serif">t</mml:mi><mml:mn mathvariant="sans-serif">2</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi mathvariant="sans-serif">t</mml:mi><mml:mn mathvariant="sans-serif">1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mn>5</mml:mn><mml:mo>&#x02010;</mml:mo><mml:mtext mathvariant="normal">Glycerol</mml:mtext><mml:mspace width="0.25em"/><mml:mi mathvariant="sans-serif">T</mml:mi><mml:mi mathvariant="sans-serif">T</mml:mi><mml:msub><mml:mi mathvariant="sans-serif">R</mml:mi><mml:mrow><mml:mi mathvariant="sans-serif">t</mml:mi><mml:mn mathvariant="sans-serif">1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="sans-serif">d</mml:mi><mml:mn mathvariant="sans-serif">5</mml:mn><mml:mo>&#x02010;</mml:mo><mml:mtext mathvariant="normal">Glycerol</mml:mtext><mml:mspace width="0.25em"/><mml:mi mathvariant="sans-serif">T</mml:mi><mml:mi mathvariant="sans-serif">T</mml:mi><mml:msub><mml:mi mathvariant="sans-serif">R</mml:mi><mml:mrow><mml:mi mathvariant="sans-serif">t</mml:mi><mml:mn mathvariant="sans-serif">2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mn mathvariant="sans-serif">2</mml:mn></mml:mfrac></mml:mrow></mml:mfrac></mml:math></disp-formula>
<disp-formula id="dom12899-disp-0005"><label>(5)</label><mml:math id="nlm-math-5"><mml:mi mathvariant="sans-serif">R</mml:mi><mml:mi mathvariant="sans-serif">d</mml:mi><mml:mspace width="0.25em"/><mml:mtext mathvariant="normal">Glycero</mml:mtext><mml:msub><mml:mi mathvariant="sans-serif">l</mml:mi><mml:mrow><mml:mi mathvariant="sans-serif">t</mml:mi><mml:mn mathvariant="sans-serif">2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi mathvariant="sans-serif">R</mml:mi><mml:mi mathvariant="sans-serif">a</mml:mi><mml:mspace width="0.25em"/><mml:mtext mathvariant="normal">Glycero</mml:mtext><mml:msub><mml:mi mathvariant="sans-serif">l</mml:mi><mml:mrow><mml:mi mathvariant="sans-serif">t</mml:mi><mml:mn mathvariant="sans-serif">2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="sans-serif">p</mml:mi><mml:mi mathvariant="sans-serif">V</mml:mi><mml:mo>&#x000d7;</mml:mo><mml:mfrac><mml:mrow><mml:mfenced open="[" close="]"><mml:mrow><mml:mtext mathvariant="normal">Glycero</mml:mtext><mml:msub><mml:mi mathvariant="sans-serif">l</mml:mi><mml:mrow><mml:mi mathvariant="sans-serif">t</mml:mi><mml:mn mathvariant="sans-serif">2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>&#x02212;</mml:mo><mml:mfenced open="[" close="]"><mml:mrow><mml:mtext mathvariant="normal">Glycero</mml:mtext><mml:msub><mml:mi mathvariant="sans-serif">l</mml:mi><mml:mrow><mml:mi mathvariant="sans-serif">t</mml:mi><mml:mn mathvariant="sans-serif">1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="sans-serif">t</mml:mi><mml:mn mathvariant="sans-serif">2</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi mathvariant="sans-serif">t</mml:mi><mml:mn mathvariant="sans-serif">1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula>
</p><p>Non&#x02010;steady state values for Ra and Rd Glucose were calculated as above, substituting glucose for glycerol, with the addition that the GIR was subtracted from the total Ra glucose to determine the endogenous glucose production as in Equation <xref rid="dom12899-disp-0003" ref-type="disp-formula">3</xref>. The effective volume of distribution (pV) used for glycerol was 230&#x02009;mL/kg.<xref rid="dom12899-bib-0019" ref-type="ref">19</xref>, <xref rid="dom12899-bib-0020" ref-type="ref">20</xref> For glucose, different values were tested for the pV which comprised 40, 100 and 150&#x02009;mL/kg.<xref rid="dom12899-bib-0019" ref-type="ref">19</xref> The results were not significantly altered by any of these pV values, probably because d2&#x02010;glucose enrichment was not significantly altered by adrenaline infusion. The results presented for glucose kinetics are those using 100&#x02009;mL/kg as the pV.</p></sec><sec id="dom12899-sec-0013"><label>2.5</label><title>Statistical analysis</title><p>Data are presented as mean&#x02009;&#x000b1;&#x02009;SEM. SPSS version 19 was used for all analyses. Comparisons between phases (ie, effect of glucocorticoids during steady state) were tested by 2&#x02010;way repeated measures ANOVA with post&#x02010;hoc testing performed using Fisher's least squares differences (LSD) test with the effect of insulin as an independent variable. Comparisons over time (ie, effect of adrenaline infusion) were tested by 2&#x02010;way repeated measures ANOVA with post&#x02010;hoc LSD testing, with effects of insulin and glucocorticoids as independent variables. <italic>P</italic>&#x02009;&#x0003c;&#x02009;.05 was considered significant.</p></sec></sec><sec id="dom12899-sec-0014"><label>3</label><title>RESULTS</title><sec id="dom12899-sec-0015"><label>3.1</label><title>Regulation of lipolysis by glucocorticoids <styled-content style="italic-in-any-context">in vivo</styled-content>
</title><p>Subject characteristics are shown in Table <xref rid="dom12899-tbl-0001" ref-type="table-wrap">1</xref>. Subjects in the low and high insulin groups were of similar age, weight and blood pressure and had similar biochemical measurements.</p><table-wrap id="dom12899-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Anthropometric and fasting biochemical measurements</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" valign="bottom" colspan="1"/><th colspan="3" align="left" valign="bottom" rowspan="1">Low insulin (n&#x02009;=&#x02009;10)</th><th colspan="3" align="left" valign="bottom" rowspan="1">High insulin (n&#x02009;=&#x02009;10)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Low GC</th><th align="left" valign="bottom" rowspan="1" colspan="1">Medium GC</th><th align="left" valign="bottom" rowspan="1" colspan="1">High GC</th><th align="left" valign="bottom" rowspan="1" colspan="1">Low GC</th><th align="left" valign="bottom" rowspan="1" colspan="1">Medium GC</th><th align="left" valign="bottom" rowspan="1" colspan="1">High GC</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="left" valign="top" rowspan="1" colspan="1">36.9&#x02009;&#x000b1;&#x02009;4.7</td><td align="left" valign="top" rowspan="1" colspan="1">37.0&#x02009;&#x000b1;&#x02009;4.7</td><td align="left" valign="top" rowspan="1" colspan="1">36.9&#x02009;&#x000b1;&#x02009;4.7</td><td align="left" valign="top" rowspan="1" colspan="1">29.9&#x02009;&#x000b1;&#x02009;5.2</td><td align="left" valign="top" rowspan="1" colspan="1">30.0&#x02009;&#x000b1;&#x02009;5.2</td><td align="left" valign="top" rowspan="1" colspan="1">29.9&#x02009;&#x000b1;&#x02009;5.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight (kg)</td><td align="left" valign="top" rowspan="1" colspan="1">74.6&#x02009;&#x000b1;&#x02009;2.1</td><td align="left" valign="top" rowspan="1" colspan="1">75.3&#x02009;&#x000b1;&#x02009;2.0</td><td align="left" valign="top" rowspan="1" colspan="1">75.1&#x02009;&#x000b1;&#x02009;2.3</td><td align="left" valign="top" rowspan="1" colspan="1">76.6&#x02009;&#x000b1;&#x02009;2.8</td><td align="left" valign="top" rowspan="1" colspan="1">76.9&#x02009;&#x000b1;&#x02009;2.9</td><td align="left" valign="top" rowspan="1" colspan="1">76.7&#x02009;&#x000b1;&#x02009;2.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">23.2&#x02009;&#x000b1;&#x02009;0.5</td><td align="left" valign="top" rowspan="1" colspan="1">23.5&#x02009;&#x000b1;&#x02009;0.5</td><td align="left" valign="top" rowspan="1" colspan="1">23.4&#x02009;&#x000b1;&#x02009;0.6</td><td align="left" valign="top" rowspan="1" colspan="1">24.0&#x02009;&#x000b1;&#x02009;0.4</td><td align="left" valign="top" rowspan="1" colspan="1">24.1&#x02009;&#x000b1;&#x02009;0.5</td><td align="left" valign="top" rowspan="1" colspan="1">24.1&#x02009;&#x000b1;&#x02009;0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fat mass (kg)</td><td align="left" valign="top" rowspan="1" colspan="1">13.6&#x02009;&#x000b1;&#x02009;0.8</td><td align="left" valign="top" rowspan="1" colspan="1">14.1&#x02009;&#x000b1;&#x02009;1.0</td><td align="left" valign="top" rowspan="1" colspan="1">14.1&#x02009;&#x000b1;&#x02009;0.9</td><td align="left" valign="top" rowspan="1" colspan="1">12.7&#x02009;&#x000b1;&#x02009;1.2</td><td align="left" valign="top" rowspan="1" colspan="1">13.4&#x02009;&#x000b1;&#x02009;1.3</td><td align="left" valign="top" rowspan="1" colspan="1">13.0&#x02009;&#x000b1;&#x02009;1.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Temperature (&#x000b0;C)</td><td align="left" valign="top" rowspan="1" colspan="1">36.6&#x02009;&#x000b1;&#x02009;0.2</td><td align="left" valign="top" rowspan="1" colspan="1">36.6&#x02009;&#x000b1;&#x02009;0.1</td><td align="left" valign="top" rowspan="1" colspan="1">36.5&#x02009;&#x000b1;&#x02009;0.2</td><td align="left" valign="top" rowspan="1" colspan="1">36.6&#x02009;&#x000b1;&#x02009;0.1</td><td align="left" valign="top" rowspan="1" colspan="1">36.7&#x02009;&#x000b1;&#x02009;0.1</td><td align="left" valign="top" rowspan="1" colspan="1">36.7&#x02009;&#x000b1;&#x02009;0.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cholesterol (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">3.9&#x02009;&#x000b1;&#x02009;0.2</td><td align="left" valign="top" rowspan="1" colspan="1">4.3&#x02009;&#x000b1;&#x02009;0.1</td><td align="left" valign="top" rowspan="1" colspan="1">4.1&#x02009;&#x000b1;&#x02009;0.2</td><td align="left" valign="top" rowspan="1" colspan="1">4.2&#x02009;&#x000b1;&#x02009;0.3</td><td align="left" valign="top" rowspan="1" colspan="1">4.2&#x02009;&#x000b1;&#x02009;0.3</td><td align="left" valign="top" rowspan="1" colspan="1">4.3&#x02009;&#x000b1;&#x02009;0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Triglycerides (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.9&#x02009;&#x000b1;&#x02009;0.1</td><td align="left" valign="top" rowspan="1" colspan="1">0.9&#x02009;&#x000b1;&#x02009;0.1</td><td align="left" valign="top" rowspan="1" colspan="1">0.9&#x02009;&#x000b1;&#x02009;0.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.0&#x02009;&#x000b1;&#x02009;0.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.0&#x02009;&#x000b1;&#x02009;0.2</td><td align="left" valign="top" rowspan="1" colspan="1">0.8&#x02009;&#x000b1;&#x02009;0.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NEFAs (&#x000b5;mol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">286&#x02009;&#x000b1;&#x02009;37</td><td align="left" valign="top" rowspan="1" colspan="1">288&#x02009;&#x000b1;&#x02009;31</td><td align="left" valign="top" rowspan="1" colspan="1">341&#x02009;&#x000b1;&#x02009;38</td><td align="left" valign="top" rowspan="1" colspan="1">317&#x02009;&#x000b1;&#x02009;40</td><td align="left" valign="top" rowspan="1" colspan="1">292&#x02009;&#x000b1;&#x02009;53</td><td align="left" valign="top" rowspan="1" colspan="1">254&#x02009;&#x000b1;&#x02009;42</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Heart rate (bpm) (SS)</td><td align="left" valign="top" rowspan="1" colspan="1">61.0&#x02009;&#x000b1;&#x02009;2.9</td><td align="left" valign="top" rowspan="1" colspan="1">62.7&#x02009;&#x000b1;&#x02009;2.8</td><td align="left" valign="top" rowspan="1" colspan="1">59.7&#x02009;&#x000b1;&#x02009;2.1</td><td align="left" valign="top" rowspan="1" colspan="1">59.4&#x02009;&#x000b1;&#x02009;2.8</td><td align="left" valign="top" rowspan="1" colspan="1">59.2&#x02009;&#x000b1;&#x02009;2.3</td><td align="left" valign="top" rowspan="1" colspan="1">61.4&#x02009;&#x000b1;&#x02009;2.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Heart rate (bpm) (ADR)</td><td align="left" valign="top" rowspan="1" colspan="1">66.4&#x02009;&#x000b1;&#x02009;2.3</td><td align="left" valign="top" rowspan="1" colspan="1">69.6&#x02009;&#x000b1;&#x02009;3.0</td><td align="left" valign="top" rowspan="1" colspan="1">76.1&#x02009;&#x000b1;&#x02009;1.9*#</td><td align="left" valign="top" rowspan="1" colspan="1">67.5&#x02009;&#x000b1;&#x02009;2.3</td><td align="left" valign="top" rowspan="1" colspan="1">68.7&#x02009;&#x000b1;&#x02009;3.2</td><td align="left" valign="top" rowspan="1" colspan="1">75.7&#x02009;&#x000b1;&#x02009;2.7**##</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Systolic BP (mm Hg) (SS)</td><td align="left" valign="top" rowspan="1" colspan="1">120.8&#x02009;&#x000b1;&#x02009;2.1</td><td align="left" valign="top" rowspan="1" colspan="1">122.1&#x02009;&#x000b1;&#x02009;2.0</td><td align="left" valign="top" rowspan="1" colspan="1">123.4&#x02009;&#x000b1;&#x02009;2.4</td><td align="left" valign="top" rowspan="1" colspan="1">119.1&#x02009;&#x000b1;&#x02009;2.7</td><td align="left" valign="top" rowspan="1" colspan="1">120.5&#x02009;&#x000b1;&#x02009;2.2</td><td align="left" valign="top" rowspan="1" colspan="1">124.4&#x02009;&#x000b1;&#x02009;2.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Systolic BP (mm Hg) (ADR)</td><td align="left" valign="top" rowspan="1" colspan="1">126.4&#x02009;&#x000b1;&#x02009;2.7</td><td align="left" valign="top" rowspan="1" colspan="1">127.3&#x02009;&#x000b1;&#x02009;2.9</td><td align="left" valign="top" rowspan="1" colspan="1">131.3&#x02009;&#x000b1;&#x02009;3.6</td><td align="left" valign="top" rowspan="1" colspan="1">127.6&#x02009;&#x000b1;&#x02009;3.2</td><td align="left" valign="top" rowspan="1" colspan="1">131.1&#x02009;&#x000b1;&#x02009;2.7</td><td align="left" valign="top" rowspan="1" colspan="1">130.7&#x02009;&#x000b1;&#x02009;5.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diastolic BP (mm Hg)(SS)</td><td align="left" valign="top" rowspan="1" colspan="1">72.1&#x02009;&#x000b1;&#x02009;2.5</td><td align="left" valign="top" rowspan="1" colspan="1">74.2&#x02009;&#x000b1;&#x02009;2.2</td><td align="left" valign="top" rowspan="1" colspan="1">73.4&#x02009;&#x000b1;&#x02009;1.9</td><td align="left" valign="top" rowspan="1" colspan="1">68.8&#x02009;&#x000b1;&#x02009;1.9</td><td align="left" valign="top" rowspan="1" colspan="1">69.4&#x02009;&#x000b1;&#x02009;1.9</td><td align="left" valign="top" rowspan="1" colspan="1">69.8&#x02009;&#x000b1;&#x02009;1.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diastolic BP (mm Hg) (ADR)</td><td align="left" valign="top" rowspan="1" colspan="1">69.7&#x02009;&#x000b1;&#x02009;2.2</td><td align="left" valign="top" rowspan="1" colspan="1">67.3&#x02009;&#x000b1;&#x02009;2.5</td><td align="left" valign="top" rowspan="1" colspan="1">65.7&#x02009;&#x000b1;&#x02009;2.1</td><td align="left" valign="top" rowspan="1" colspan="1">63.0&#x02009;&#x000b1;&#x02009;1.7</td><td align="left" valign="top" rowspan="1" colspan="1">65.3&#x02009;&#x000b1;&#x02009;2.0</td><td align="left" valign="top" rowspan="1" colspan="1">61.6&#x02009;&#x000b1;&#x02009;2.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total glucose infused (g)</td><td align="left" valign="top" rowspan="1" colspan="1">21.4&#x02009;&#x000b1;&#x02009;2.8</td><td align="left" valign="top" rowspan="1" colspan="1">12.7&#x02009;&#x000b1;&#x02009;1.9*</td><td align="left" valign="top" rowspan="1" colspan="1">14.9&#x02009;&#x000b1;&#x02009;2.3*</td><td align="left" valign="top" rowspan="1" colspan="1">62.5&#x02009;&#x000b1;&#x02009;6.5</td><td align="left" valign="top" rowspan="1" colspan="1">54.5&#x02009;&#x000b1;&#x02009;7.6</td><td align="left" valign="top" rowspan="1" colspan="1">53.8&#x02009;&#x000b1;&#x02009;6.8</td></tr></tbody></table><table-wrap-foot><fn id="dom12899-note-0002"><p>Data are given as mean&#x02009;&#x000b1;&#x02009;<styled-content style="fixed-case">SEM</styled-content>. Steady state (<styled-content style="fixed-case">SS</styled-content>) data are the mean values obtained from t&#x02009;+&#x02009;180 to t&#x02009;+&#x02009;240&#x02009;minutes of the infusion. Adrenaline (<styled-content style="fixed-case">ADR</styled-content>) data are the mean values obtained from t&#x02009;+&#x02009;285 to t&#x02009;+&#x02009;345&#x02009;minutes. Adrenaline increased heart rate and systolic <styled-content style="fixed-case">BP</styled-content> and decreased diastolic <styled-content style="fixed-case">BP</styled-content> (all <styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.01). Total glucose infused during the protocol was increased in the high insulin group (<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.001). <styled-content style="fixed-case">NEFAs</styled-content>&#x02009;=&#x02009;non&#x02010;esterified fatty acids. *<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.05, **<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.01 vs low <styled-content style="fixed-case">GC</styled-content>; #<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.05, ##<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.01 vs medium <styled-content style="fixed-case">GC</styled-content>.</p></fn></table-wrap-foot></table-wrap><sec id="dom12899-sec-0016"><label>3.1.1</label><title>Baseline measurements at study visits</title><p>Cortisol concentrations were different between GC phases (all <italic>P</italic>&#x02009;&#x0003c;&#x02009;.01) (Figure <xref rid="dom12899-fig-0001" ref-type="fig">1</xref>A). Fasting insulin, glucose, growth hormone, glucagon and adrenaline (Figure <xref rid="dom12899-fig-0001" ref-type="fig">1</xref>), NEFAs and glycerol (data not shown) were similar between insulin groups and unaltered by GC phase.</p></sec><sec id="dom12899-sec-0017"><label>3.1.2</label><title>Steady state measurements</title><p>Cortisol concentrations remained different between phases (all <italic>P</italic>&#x02009;&#x0003c;&#x02009;.001) and were similar between high and low insulin groups (Figure <xref rid="dom12899-fig-0001" ref-type="fig">1</xref>A). Insulin concentrations were increased in the high insulin group (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.01) (Figure <xref rid="dom12899-fig-0001" ref-type="fig">1</xref>B). Glucose, growth hormone, glucagon and adrenaline concentrations were similar between GC phases and insulin groups (Figure <xref rid="dom12899-fig-0001" ref-type="fig">1</xref>C&#x02010;F). Concentrations of these hormones and glucose remained stable during steady state. High GC tended to increase systolic blood pressure (<italic>P</italic>&#x02009;=&#x02009;.06, Table <xref rid="dom12899-tbl-0001" ref-type="table-wrap">1</xref>).</p><sec id="dom12899-sec-0018"><label>3.1.2.1</label><title>Effects of glucocorticoids on lipolysis and glucose kinetics</title><p>Ra glycerol and NEFA concentrations were suppressed by high insulin (Figure <xref rid="dom12899-fig-0002" ref-type="fig">2</xref>A,B). The high GC phase increased Ra glycerol and NEFAs only in the high insulin group (Figure <xref rid="dom12899-fig-0002" ref-type="fig">2</xref>A,B).</p><fig fig-type="Figure" xml:lang="en" id="dom12899-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Effect of glucocorticoids on lipolysis and glucose kinetics <styled-content style="italic-in-any-context">in vivo</styled-content>. Data are given as mean&#x02009;&#x000b1;&#x02009;<styled-content style="fixed-case">SEM</styled-content> for n&#x02009;=&#x02009;10 for low insulin (comprising low glucocorticoid [<styled-content style="fixed-case">GC</styled-content>] phase [white columns], medium <styled-content style="fixed-case">GC</styled-content> [grey columns] and high <styled-content style="fixed-case">GC</styled-content> [black columns]) and high insulin (low <styled-content style="fixed-case">GC</styled-content> [striped columns], medium <styled-content style="fixed-case">GC</styled-content> [checked columns] and high <styled-content style="fixed-case">GC</styled-content> [bricked columns]) groups. <styled-content style="fixed-case">A</styled-content>, <styled-content style="fixed-case">H</styled-content>igh <styled-content style="fixed-case">GC</styled-content> increased the rate of appearance of glycerol in the high insulin group at steady state (t&#x02009;+&#x02009;180&#x02010;240&#x02009;minutes) and during adrenaline infusion (t&#x02009;+&#x02009;285&#x02010;345&#x02009;minutes). <styled-content style="fixed-case">B</styled-content>, <styled-content style="fixed-case">H</styled-content>igh <styled-content style="fixed-case">GC</styled-content> increased <styled-content style="fixed-case">NEFA</styled-content> concentrations in the high insulin group during steady state and in both insulin groups during adrenaline infusion. High insulin suppressed the rate of appearance of glycerol and <styled-content style="fixed-case">NEFAs</styled-content> (both <styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.001). <styled-content style="fixed-case">GC</styled-content> phase did not alter either <styled-content style="fixed-case">C</styled-content>, endogenous glucose production or <styled-content style="fixed-case">D</styled-content>, glucose disposal. Glucose disposal was increased in the high insulin group during steady state (<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.01) but not during adrenaline infusion. Adrenaline decreased glucose disposal in both groups (<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.01). *<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.05 vs low <styled-content style="fixed-case">GC</styled-content>, #<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.05 vs medium <styled-content style="fixed-case">GC</styled-content>
</p></caption><graphic id="nlm-graphic-3" xlink:href="DOM-19-883-g002"/></fig><p>The high insulin group required more intravenous glucose to maintain glucose concentrations over the 345&#x02010;minute protocol (Table <xref rid="dom12899-tbl-0001" ref-type="table-wrap">1</xref>). In the low insulin group, the medium and high GC phases reduced the required glucose infusion rate (Table <xref rid="dom12899-tbl-0001" ref-type="table-wrap">1</xref>). Endogenous glucose production (EGP) and Rd glucose were unchanged by GC phase in either insulin group (Figure <xref rid="dom12899-fig-0002" ref-type="fig">2</xref>C,D).</p></sec></sec><sec id="dom12899-sec-0019"><label>3.1.3</label><title>Measurements during adrenaline infusion</title><p>Adrenaline concentrations achieved during the infusion were similar to those observed during exercise<xref rid="dom12899-bib-0021" ref-type="ref">21</xref> (Figure <xref rid="dom12899-fig-0001" ref-type="fig">1</xref>E). Adrenaline increased heart rate and systolic blood pressure and decreased diastolic blood pressure (Table <xref rid="dom12899-tbl-0001" ref-type="table-wrap">1</xref>). The high GC phase increased heart rate during the adrenaline infusion in both insulin groups (Table <xref rid="dom12899-tbl-0001" ref-type="table-wrap">1</xref>).</p><sec id="dom12899-sec-0020"><label>3.1.3.1</label><title>Effects of glucocorticoids on lipolysis and glucose kinetics</title><p>Adrenaline increased Ra glycerol and NEFAs (all phases <italic>P</italic>&#x02009;&#x0003c;&#x02009;.001) (Figure <xref rid="dom12899-fig-0002" ref-type="fig">2</xref>A,B). High GC increased Ra glycerol and NEFAs in the high insulin group (Figure <xref rid="dom12899-fig-0002" ref-type="fig">2</xref>A,B). In contrast, high GC did not increase Ra glycerol in the low insulin group, although NEFAs were increased (Figure <xref rid="dom12899-fig-0002" ref-type="fig">2</xref>A,B). GC phase did not alter Rd glycerol (data not shown).</p><p>Adrenaline increased glucose concentrations only in the high insulin group (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.05) (Figure <xref rid="dom12899-fig-0001" ref-type="fig">1</xref>C) and decreased Rd glucose in both insulin groups (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.01) (Figure <xref rid="dom12899-fig-0002" ref-type="fig">2</xref>D). GC phase did not alter EGP or Rd glucose in either insulin group (Figure <xref rid="dom12899-fig-0002" ref-type="fig">2</xref>C,D).</p></sec></sec><sec id="dom12899-sec-0021"><label>3.1.4</label><title>Glucocorticoids increase expression of key genes in the lipolytic pathway</title><p>Adipose tissue was analysed in low (n&#x02009;=&#x02009;10) and high (n&#x02009;=&#x02009;9) insulin groups. Adipose tissue from one subject in the high insulin group was not obtained because of technical difficulties with the biopsy procedure. The high GC phase increased mRNA levels of key lipolytic genes adipose triglyceride lipase (ATGL), hormone sensitive lipase (HSL) and comparative gene identification&#x02010;58 (CGI&#x02010;58) and decreased G0/G1 switch 2 (<italic>G0S2</italic>) (Figure <xref rid="dom12899-fig-0003" ref-type="fig">3</xref>A,B). In addition, high GC decreased transcript levels of the glucocorticoid (GR&#x003b1;) and mineralocorticoid receptor (MR). Despite the GC phase not increasing lipolysis in the low insulin group, GC similarly regulated the lipolytic pathway in both insulin groups (Figure <xref rid="dom12899-fig-0003" ref-type="fig">3</xref>A,B). Perilipin 1, <italic>G0S2</italic> and lipoprotein lipase were increased by high insulin (Figure <xref rid="dom12899-fig-0003" ref-type="fig">3</xref>B).</p><fig fig-type="Figure" xml:lang="en" id="dom12899-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Glucocorticoid regulation of adipose <styled-content style="fixed-case">mRNA</styled-content> levels <styled-content style="italic-in-any-context">in vivo</styled-content> and <styled-content style="italic-in-any-context">in vitro.</styled-content>
<styled-content style="fixed-case">A</styled-content>, <styled-content style="fixed-case">B</styled-content>, <styled-content style="fixed-case">D</styled-content>ata are given as mean&#x02009;&#x000b1;&#x02009;<styled-content style="fixed-case">SEM</styled-content> for low glucocorticoid (<styled-content style="fixed-case">GC</styled-content>) (white columns), medium <styled-content style="fixed-case">GC</styled-content> (grey columns) and high <styled-content style="fixed-case">GC</styled-content> (black columns) for <styled-content style="fixed-case">A</styled-content>, low insulin (n&#x02009;=&#x02009;10) and <styled-content style="fixed-case">B</styled-content>, high insulin (n&#x02009;=&#x02009;9) groups. Medium or high <styled-content style="fixed-case">GC</styled-content> increased <styled-content style="fixed-case">mRNA</styled-content> levels of <styled-content style="fixed-case">ATGL</styled-content>, <styled-content style="fixed-case">HSL</styled-content> and <styled-content style="fixed-case">CGI</styled-content>&#x02010;58 and suppressed <styled-content style="fixed-case">G0S2</styled-content>. High insulin increased perilipin&#x02010;1, <styled-content style="fixed-case">G0S2</styled-content> and <styled-content style="fixed-case">LpL mRNA</styled-content> levels. <styled-content style="fixed-case">C</styled-content>,<styled-content style="fixed-case">D</styled-content>, <styled-content style="fixed-case">D</styled-content>ata are given as mean&#x02009;&#x000b1;&#x02009;<styled-content style="fixed-case">SEM</styled-content> for <styled-content style="fixed-case">C</styled-content>, subcutaneous and <styled-content style="fixed-case">D</styled-content>, visceral adipocytes (both n=11) cultured for 24&#x02009;hours in 0&#x02009;n<styled-content style="fixed-case">M</styled-content> (white columns), 100&#x02009;n<styled-content style="fixed-case">M</styled-content> (grey columns) or 1000&#x02009;n<styled-content style="fixed-case">M</styled-content> cortisol (black columns). While <styled-content style="italic-in-any-context">in vitro</styled-content> regulation of transcripts by cortisol was similar to <styled-content style="italic-in-any-context">in vivo</styled-content> data, cortisol also increased perilipin&#x02010;1, <styled-content style="fixed-case">LpL</styled-content>, <styled-content style="fixed-case">PEDF</styled-content>, <styled-content style="fixed-case">PDE3b</styled-content> and decreased <styled-content style="fixed-case">MGL</styled-content> levels <styled-content style="italic-in-any-context">in vitro</styled-content>. <styled-content style="fixed-case">HSL</styled-content> was increased by cortisol only in the subcutaneous adipocytes. *<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.05, **<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.01 vs low <styled-content style="fixed-case">GC</styled-content>/0&#x02009;n<styled-content style="fixed-case">M</styled-content>; #<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.05, ##<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.01 vs medium <styled-content style="fixed-case">GC</styled-content>/100&#x02009;n<styled-content style="fixed-case">M</styled-content>. $<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.05 vs low insulin group</p></caption><graphic id="nlm-graphic-5" xlink:href="DOM-19-883-g003"/></fig></sec></sec><sec id="dom12899-sec-0022"><label>3.2</label><title>Regulation of lipolysis by glucocorticoids <styled-content style="italic-in-any-context">in vitro</styled-content>
</title><p>Cortisol did not increase glycerol appearance (a measure of lipolysis) during incubations without insulin or adrenaline in subcutaneous or visceral differentiated pre&#x02010;adipocytes in agreement with <italic>in vivo</italic> data (Figure <xref rid="dom12899-fig-0004" ref-type="fig">4</xref>). Insulin suppressed and adrenaline increased glycerol appearance in both subcutaneous and visceral adipocytes. In the presence of insulin, cortisol increased glycerol appearance in subcutaneous but not visceral adipocytes (Figure <xref rid="dom12899-fig-0004" ref-type="fig">4</xref>). In the presence of adrenaline, cortisol suppressed glycerol appearance in visceral adipocytes.</p><fig fig-type="Figure" xml:lang="en" id="dom12899-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Glucocorticoid regulation of lipolysis <styled-content style="italic-in-any-context">in vitro.</styled-content> Data are given as mean&#x02009;&#x000b1;&#x02009;<styled-content style="fixed-case">SEM</styled-content> for glycerol release from paired primary human subcutaneous (<styled-content style="fixed-case">A</styled-content>) and visceral adipocytes (<styled-content style="fixed-case">B</styled-content>) (both n=11) cultured in 0&#x02009;n<styled-content style="fixed-case">M</styled-content> (white columns), 100&#x02009;n<styled-content style="fixed-case">M</styled-content> (grey columns) or 1000&#x02009;n<styled-content style="fixed-case">M</styled-content> cortisol (black columns) for 24&#x02009;hours in the presence of either vehicle, 100&#x02009;p<styled-content style="fixed-case">M</styled-content> insulin or 10&#x02009;&#x000b5;<styled-content style="fixed-case">M</styled-content> adrenaline. Insulin suppressed and adrenaline increased glycerol release. Cortisol did not alter glycerol release from adipocytes in vehicle treated cells, but increased glycerol release in subcutaneous adipocytes co&#x02010;incubated with insulin. Cortisol decreased glycerol release in visceral adipocytes co&#x02010;incubated with adrenaline. *<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.05 vs 0&#x02009;n<styled-content style="fixed-case">M</styled-content>; $<styled-content style="fixed-case"><styled-content style="italic-in-any-context">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.05, $$$<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.001 vs vehicle 0&#x02009;n<styled-content style="fixed-case">M</styled-content>
</p></caption><graphic id="nlm-graphic-7" xlink:href="DOM-19-883-g004"/></fig><p>As <italic>in vivo</italic>, cortisol increased mRNA levels of ATGL, HSL and CGI&#x02010;58 and suppressed <italic>G0S2</italic>, GR&#x003b1; and MR in subcutaneous adipocytes (Figure <xref rid="dom12899-fig-0003" ref-type="fig">3</xref>C). Similar results were observed in visceral adipocytes; however, cortisol did not alter HSL (Figure <xref rid="dom12899-fig-0003" ref-type="fig">3</xref>D). In contrast with <italic>in vivo</italic> data, cortisol increased mRNA levels of perilipin&#x02010;1, <italic>LPL</italic>, PEDF and <italic>PDE3B</italic> and suppressed MGL.</p></sec></sec><sec id="dom12899-sec-0023"><label>4</label><title>DISCUSSION</title><p>This work shows that glucocorticoids are dependent on insulin and/or adrenaline in order to increase whole body lipolysis <italic>in vivo</italic>. In the presence of low insulin levels (c. 16&#x02009;mU/L), even circulating cortisol concentrations of c. 1400&#x02009;nM did not increase Ra glycerol or NEFA concentrations. Conversely, in slightly higher insulin concentrations (c. 22&#x02009;mU/L) designed to suppress lipolysis by 50%, high cortisol concentrations increased Ra glycerol by 20% to 25%, showing that cortisol antagonizes the effect of insulin. In addition, high cortisol augmented the pro&#x02010;lipolytic effects of adrenaline in the high insulin group. However, high GC did not enhance Ra glycerol in the low insulin group during adrenaline infusion, but did increase circulating NEFAs. Therefore, our study provides the first <italic>in vivo</italic> evidence that glucocorticoids have permissive effects on lipolysis in humans. Although our data might appear to contrast with some previous work,<xref rid="dom12899-bib-0007" ref-type="ref">7</xref>, <xref rid="dom12899-bib-0008" ref-type="ref">8</xref>, <xref rid="dom12899-bib-0009" ref-type="ref">9</xref> in one of those studies replacement glucagon was not infused, while we infused a lower insulin dose than the other 2 studies and, as we have shown, a &#x0201c;threshold&#x0201d; insulin dose is required to mediate the lipolytic effects of cortisol. In addition, unlike the other studies, we used metyrapone to control cortisol levels during all phases and performed longer treatment with hydrocortisone. However, metyrapone does not alter lipolysis independently of its effects on cortisol,<xref rid="dom12899-bib-0010" ref-type="ref">10</xref> while cortisol accumulates slowly in adipose tissue, meaning that a longer duration would be more likely to identify effects on lipolysis.<xref rid="dom12899-bib-0022" ref-type="ref">22</xref>
</p><p>Although previous studies have tested how glucocorticoids regulate the lipolytic pathway in rodents (by increasing ATGL and HSL),<xref rid="dom12899-bib-0004" ref-type="ref">4</xref>, <xref rid="dom12899-bib-0023" ref-type="ref">23</xref> this had not been tested <italic>in vivo</italic> in humans. Glucocorticoids act predominantly by altering transcription of target genes and we found that cortisol increased transcription of the key lipases ATGL (and the co&#x02010;factor CGI&#x02010;58) and HSL and suppressed the negative lipolytic regulator <italic>G0S2</italic>. Interestingly, this regulation was similar in both insulin groups, despite cortisol not enhancing lipolysis during low insulin. This shows that glucocorticoids &#x0201c;prime&#x0201d; the pathway, to enhance lipolysis in response to adrenaline or to antagonize the effects of insulin. Additional genes outside the classic lipolytic pathway have been implicated in the lipolytic effects of glucocorticoids, such as phosphodiesterase 3b,<xref rid="dom12899-bib-0004" ref-type="ref">4</xref> pigment epithelium derived factor<xref rid="dom12899-bib-0024" ref-type="ref">24</xref> and angiopoietin&#x02010;like 4;<xref rid="dom12899-bib-0025" ref-type="ref">25</xref> however, in our study, cortisol did not alter mRNA levels of these genes <italic>in vivo,</italic> while <italic>in vitro</italic> PDE3b levels were in fact increased, suggesting that glucocorticoids do not antagonize the effect of insulin via this pathway in humans. There are additional mechanisms through which glucocorticoids might promote or inhibit the effects of adrenaline and insulin which we did not explore; for example, glucocorticoids increase the number of pro&#x02010;lipolytic &#x003b2;&#x02010;receptors on the adipocyte membrane,<xref rid="dom12899-bib-0026" ref-type="ref">26</xref>, <xref rid="dom12899-bib-0027" ref-type="ref">27</xref> decrease the number of anti&#x02010;lipolytic &#x003b1;2&#x02010;receptors<xref rid="dom12899-bib-0028" ref-type="ref">28</xref> and increase cAMP levels in rodent adipocytes.<xref rid="dom12899-bib-0004" ref-type="ref">4</xref> However, glucocorticoids enhance basal lipolysis in rodents,<xref rid="dom12899-bib-0004" ref-type="ref">4</xref>, <xref rid="dom12899-bib-0023" ref-type="ref">23</xref> which we did not observe in humans, highlighting species&#x02010;specific differences in the glucocorticoid regulation of lipolysis. Interestingly, high insulin increased mRNA levels of perilipin 1, <italic>G0S2</italic>
<xref rid="dom12899-bib-0029" ref-type="ref">29</xref> and lipoprotein lipase, which should all reduce lipolysis and/or promote lipogenesis, in agreement with the known effects of insulin.</p><p>Subcutaneous and visceral adipocytes arise from different cell lineages,<xref rid="dom12899-bib-0030" ref-type="ref">30</xref> and we tested whether glucocorticoids have depot&#x02010;specific effects in paired subcutaneous and visceral adipocytes. Importantly, insulin suppressed and adrenaline stimulated glycerol release similarly in both cell types. In agreement with <italic>in vivo</italic> data, cortisol increased lipolysis only in the presence of insulin in the subcutaneous adipocytes and did not increase lipolysis in the presence of adrenaline without insulin. However, cortisol failed to enhance lipolysis in the visceral adipocytes even with insulin and decreased lipolysis in the presence of adrenaline. Although visceral adipose tissue accounts for only a small proportion (c. 6%) of whole body lipolysis in lean individuals,<xref rid="dom12899-bib-0031" ref-type="ref">31</xref> this may explain why chronic glucocorticoid excess causes accumulation of visceral adipose tissue. Although GR&#x003b1; and MR transcript levels were similar between depots, cortisol failed to increase HSL levels in visceral adipocytes, which could be responsible, in part, for these depot&#x02010;specific differences, as catecholamines and insulin both mediate their effects on lipolysis by phosphorylating HSL. Although we tested only the acute effects of cortisol on lipolysis, chronic glucocorticoid excess causes hyperinsulinaemia, which would suppress lipolysis and promote lipogenesis. The high GC phase only partially antagonized the insulin&#x02010;mediated suppression of lipolysis; thus, cortisol&#x02010;induced hyperinsulinaemia may offset this effect, which may explain why chronic GC excess does not necessarily increase whole&#x02010;body lipolysis.<xref rid="dom12899-bib-0032" ref-type="ref">32</xref>, <xref rid="dom12899-bib-0033" ref-type="ref">33</xref>
</p><p>It is of note that only supraphysiological cortisol concentrations increased lipolysis while cortisol levels similar to physiological early morning cortisol concentrations (c. 400&#x02009;nM) did not increase whole&#x02010;body lipolysis compared with low cortisol (c.150&#x02009;nM). This suggests that acute diurnal variation in cortisol concentrations may not substantially alter lipolysis during normal physiology, although the physiological response to &#x0201c;clamped&#x0201d; cortisol levels may differ from ultradian rhythm.<xref rid="dom12899-bib-0034" ref-type="ref">34</xref> In addition, we clamped several other hormones to prevent confounding effects, and the physiological rise in these hormones may be critical for the glucocorticoid&#x02010;dependent diurnal variation in lipolysis.<xref rid="dom12899-bib-0010" ref-type="ref">10</xref> In addition, it is possible that cortisol concentrations less than 150&#x02009;nM (eg, in Addison's disease) would have reduced lipolysis further, although <italic>in vitro</italic> 0&#x02009;nM cortisol did not reduce lipolysis compared with 100&#x02009;nM. Another unexpected finding was the absence of effect of even high cortisol concentrations on glucose uptake or production, highlighting the fact that the known effects of glucocorticoids to raise blood glucose concentrations are also permissive and are probably mediated through effects on other tissues such as the pancreas. However, the glucose infusion rate was reduced on low GC compared with the other phases in the low&#x02010;insulin group, and it is possible that, with greater numbers, we would have found a reduction in endogenous glucose production. Furthermore, cortisol may have enhanced glucose uptake and/or suppressed glucose disposal if we had infused larger doses of insulin. This protocol, however, was designed to suppress lipolysis by 50% and not to substantially alter glucose kinetics.</p><p>To conclude, the acute lipolytic effects of glucocorticoids are dependent on insulin and adrenaline and are observed in subcutaneous, but not visceral, adipose tissue solely during supraphysiological cortisol concentrations. These effects are mediated, at least in part, by enhanced transcription of ATGL, HSL and CGI&#x02010;58 and by suppression of <italic>G0S2</italic>. These findings highlight how the permissive lipolytic effects of glucocorticoids are probably mediated and indicate the importance of hormonal interactions in regulating energy balance.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom12899-supitem-0001"><caption><p>
<bold>Table</bold>
<styled-content style="fixed-case"><bold>S1</bold></styled-content>
<bold>.</bold> Participants for in vitro experiment.</p><p>
<bold>Table</bold>
<styled-content style="fixed-case"><bold>S2</bold></styled-content>
<bold>.</bold> Primer sequences for <styled-content style="fixed-case">qPCR</styled-content> and corresponding probe numbers. All assays were performed using the following primer probe sequences and the <styled-content style="fixed-case">R</styled-content>oche probe library, except for hormone sensitive lipase which was measured using the <styled-content style="fixed-case">SYBR</styled-content> green assay.</p><p>
<bold>Figure</bold>
<styled-content style="fixed-case"><bold>S1</bold></styled-content>
<bold>.</bold> The lipolytic pathway. Schematic representing the major steps in the lipolytic pathway in a lipid droplet of an adipocyte. Triacylglycerides (<styled-content style="fixed-case">TAG</styled-content>) are converted to diacylglycerides (<styled-content style="fixed-case">DAG</styled-content>) with release of a fatty acid (<styled-content style="fixed-case">FA</styled-content>) by adipose triglyceride lipase (<styled-content style="fixed-case">ATGL</styled-content>) along with <styled-content style="fixed-case">ATGL</styled-content>&#x02019;s co&#x02010;factor comparative gene identification&#x02010;58 (<styled-content style="fixed-case">CGI</styled-content>&#x02010;58). <styled-content style="fixed-case">ATGL</styled-content> function is inhibited by <styled-content style="fixed-case">G0</styled-content>/<styled-content style="fixed-case">G1</styled-content> switch 2 (<styled-content style="fixed-case">G0S2</styled-content>). <styled-content style="fixed-case">DAGs</styled-content> are converted to monoacylglycerides (<styled-content style="fixed-case">MAG</styled-content>) with <styled-content style="fixed-case">FA</styled-content> release by hormone sensitive lipase (<styled-content style="fixed-case">HSL</styled-content>) following interaction with perilipin&#x02010;1 (<styled-content style="fixed-case">PLIN</styled-content>&#x02010;1). Finally, <styled-content style="fixed-case">MAGs</styled-content> are hydrolysed by monoglyceride lipase (<styled-content style="fixed-case">MGL</styled-content>) with release of glycerol and <styled-content style="fixed-case">FA</styled-content>.</p><p>
<bold>Figure</bold>
<styled-content style="fixed-case"><bold>S2</bold></styled-content>
<bold>.</bold> Study protocol. <styled-content style="fixed-case">A</styled-content>, <styled-content style="fixed-case">F</styled-content>lowchart depicting study design, with 20 men initially randomised to either low or high insulin groups (both n&#x02009;=&#x02009;10). Subjects attended the <styled-content style="fixed-case">C</styled-content>linical <styled-content style="fixed-case">R</styled-content>esearch <styled-content style="fixed-case">F</styled-content>acility on three occasions in random order and received metyrapone +/&#x02212; hydrocortisone the evening before each study visit at 23:00 and at 07:00&#x02009;hours on the morning of their assessment to ensure glucocorticoid (<styled-content style="fixed-case">GC</styled-content>) levels were either low, medium or high. <styled-content style="fixed-case">B</styled-content>, <styled-content style="fixed-case">P</styled-content>rotocol during each study visit. Infusions were commenced at the times shown and steady state blood samples were taken between t&#x02009;+&#x02009;180 and t&#x02009;+&#x02009;240&#x02009;minutes. An adipose tissue (<styled-content style="fixed-case">AT</styled-content>) biopsy was performed at t&#x02009;+&#x02009;240&#x02009;minutes prior to commencement of an adrenaline infusion for the final hour of the protocol.</p></caption><media xlink:href="DOM-19-883-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom12899-sec-0024"><title>ACKNOWLEDGEMENTS</title><p>We thank Bruce Tulloh, Sanjaykumar Kothiya, Lucy Marshall, Julie Donnelly and Natalie Homer for their assistance, and acknowledge the financial support of NHS Research Scotland (NRS) through the Edinburgh Clinical Research Facility.</p><sec id="dom12899-sec-0025"><title>Conflict of interest</title><p>The authors have nothing to disclose.</p></sec><sec id="dom12899-sec-0026"><title>Author contributions</title><p>R. H. S and B. R. W designed the experiments. R. H. S and A. J. A. performed the <italic>in vivo</italic> experiments. R. H. S., L. E. R., A. C. B. and D. J. M. performed the <italic>in vitro</italic> experiments. R. H. S., L. E. R., D. P. M., R. A. and B. R. W. analysed data and/or contributed to discussion. R. H. S. wrote the initial draft of the manuscript which was critically reviewed by all authors.</p></sec></ack><ref-list content-type="cited-references" id="dom12899-bibl-0001"><title>REFERENCES</title><ref id="dom12899-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom12899-cit-0001">
<string-name>
<surname>Dinneen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Alzaid</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Miles</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rizza</surname>
<given-names>R</given-names>
</string-name>. <article-title>Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans</article-title>. <source>J Clin Invest</source>. <year>1993</year>;<volume>92</volume>:<fpage>2283</fpage>&#x02010;<lpage>2290</lpage>.<pub-id pub-id-type="pmid">8227343</pub-id></mixed-citation></ref><ref id="dom12899-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom12899-cit-0002">
<string-name>
<surname>Macfarlane</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Forbes</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>BR</given-names>
</string-name>. <article-title>Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome</article-title>. <source>J Endocrinol</source>. <year>2008</year>;<volume>197</volume>:<fpage>189</fpage>&#x02010;<lpage>204</lpage>.<pub-id pub-id-type="pmid">18434349</pub-id></mixed-citation></ref><ref id="dom12899-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12899-cit-0003">
<string-name>
<surname>Walker</surname>
<given-names>BR</given-names>
</string-name>. <article-title>Glucocorticoids and cardiovascular disease</article-title>. <source>Eur J Endocrinol</source>. <year>2007</year>;<volume>157</volume>:<fpage>545</fpage>&#x02010;<lpage>559</lpage>.<pub-id pub-id-type="pmid">17984234</pub-id></mixed-citation></ref><ref id="dom12899-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom12899-cit-0004">
<string-name>
<surname>Xu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Direct effect of glucocorticoids on lipolysis in adipocytes</article-title>. <source>Mol Endocrinol</source>. <year>2009</year>;<volume>23</volume>:<fpage>1161</fpage>&#x02010;<lpage>1170</lpage>.<pub-id pub-id-type="pmid">19443609</pub-id></mixed-citation></ref><ref id="dom12899-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12899-cit-0005">
<string-name>
<surname>Lee</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Fried</surname>
<given-names>SK</given-names>
</string-name>. <article-title>Glucocorticoids antagonize tumor necrosis factor&#x02010;alpha&#x02010;stimulated lipolysis and resistance to the antilipolytic effect of insulin in human adipocytes</article-title>. <source>Am J Physiol Endocrinol Metab</source>. <year>2012</year>;<volume>303</volume>:<fpage>E1126</fpage>&#x02010;<lpage>E1133</lpage>.<pub-id pub-id-type="pmid">22949029</pub-id></mixed-citation></ref><ref id="dom12899-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom12899-cit-0006">
<string-name>
<surname>Ottosson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lonnroth</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bjorntorp</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Eden</surname>
<given-names>S</given-names>
</string-name>. <article-title>Effects of cortisol and growth hormone on lipolysis in human adipose tissue</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2000</year>;<volume>85</volume>:<fpage>799</fpage>&#x02010;<lpage>803</lpage>.<pub-id pub-id-type="pmid">10690893</pub-id></mixed-citation></ref><ref id="dom12899-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12899-cit-0007">
<string-name>
<surname>Divertie</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Miles</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Stimulation of lipolysis in humans by physiological hypercortisolemia</article-title>. <source>Diabetes</source>. <year>1991</year>;<volume>40</volume>:<fpage>1228</fpage>&#x02010;<lpage>1232</lpage>.<pub-id pub-id-type="pmid">1936585</pub-id></mixed-citation></ref><ref id="dom12899-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12899-cit-0008">
<string-name>
<surname>Djurhuus</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Gravholt</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Nielsen</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Effects of cortisol on lipolysis and regional interstitial glycerol levels in humans</article-title>. <source>Am J Physiol Endocrinol Metab</source>. <year>2002</year>;<volume>283</volume>:<fpage>E172</fpage>&#x02010;<lpage>E177</lpage>.<pub-id pub-id-type="pmid">12067858</pub-id></mixed-citation></ref><ref id="dom12899-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom12899-cit-0009">
<string-name>
<surname>Djurhuus</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Gravholt</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Nielsen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pedersen</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Moller</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Schmitz</surname>
<given-names>O</given-names>
</string-name>. <article-title>Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans</article-title>. <source>Am J Physiol Endocrinol Metab</source>. <year>2004</year>;<volume>286</volume>:<fpage>E488</fpage>&#x02010;<lpage>E494</lpage>.<pub-id pub-id-type="pmid">14600073</pub-id></mixed-citation></ref><ref id="dom12899-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom12899-cit-0010">
<string-name>
<surname>Samra</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Clark</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Humphreys</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>MacDonald</surname>
<given-names>IA</given-names>
</string-name>, <string-name>
<surname>Matthews</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Frayn</surname>
<given-names>KN</given-names>
</string-name>. <article-title>Effects of morning rise in cortisol concentration on regulation of lipolysis in subcutaneous adipose tissue</article-title>. <source>Am J Physiol</source>. <year>1996</year>;<volume>271</volume>:<fpage>E996</fpage>&#x02010;<lpage>E1002</lpage>.<pub-id pub-id-type="pmid">8997217</pub-id></mixed-citation></ref><ref id="dom12899-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom12899-cit-0011">
<string-name>
<surname>Pernet</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Johnston</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Hammond</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Orskov</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Alberti</surname>
<given-names>KG</given-names>
</string-name>. <article-title>Interactions of stress hormones on lipid and carbohydrate metabolism in man with partial insulin deficiency</article-title>. <source>Eur J Clin Invest</source>. <year>1986</year>;<volume>16</volume>:<fpage>310</fpage>&#x02010;<lpage>315</lpage>.<pub-id pub-id-type="pmid">2875880</pub-id></mixed-citation></ref><ref id="dom12899-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12899-cit-0012">
<string-name>
<surname>Hazlehurst</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Gathercole</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Nasiri</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Glucocorticoids fail to cause insulin resistance in human subcutaneous adipose tissue in vivo</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2013</year>;<volume>98</volume>:<fpage>1631</fpage>&#x02010;<lpage>1640</lpage>.<pub-id pub-id-type="pmid">23426618</pub-id></mixed-citation></ref><ref id="dom12899-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom12899-cit-0013">
<string-name>
<surname>Stumvoll</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jacob</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wahl</surname>
<given-names>HG</given-names>
</string-name>, et al. <article-title>Suppression of systemic, intramuscular, and subcutaneous adipose tissue lipolysis by insulin in humans</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2000</year>;<volume>85</volume>:<fpage>3740</fpage>&#x02010;<lpage>3745</lpage>.<pub-id pub-id-type="pmid">11061533</pub-id></mixed-citation></ref><ref id="dom12899-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom12899-cit-0014">
<string-name>
<surname>Stimson</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Johnstone</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Homer</surname>
<given-names>NZ</given-names>
</string-name>, et al. <article-title>Dietary macronutrient content alters cortisol metabolism independently of body weight changes in obese men</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2007</year>;<volume>92</volume>:<fpage>4480</fpage>&#x02010;<lpage>4484</lpage>.<pub-id pub-id-type="pmid">17785367</pub-id></mixed-citation></ref><ref id="dom12899-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom12899-cit-0015">
<string-name>
<surname>van Harmelen</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Skurk</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hauner</surname>
<given-names>H</given-names>
</string-name>. <article-title>Primary culture and differentiation of human adipocyte precursor cells</article-title>. <source>Methods Mol Med</source>. <year>2005</year>;<volume>107</volume>:<fpage>125</fpage>&#x02010;<lpage>135</lpage>.<pub-id pub-id-type="pmid">15492368</pub-id></mixed-citation></ref><ref id="dom12899-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom12899-cit-0016">
<string-name>
<surname>Macfarlane</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Raubenheimer</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Preston</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with Type 2 diabetes with and without fatty liver</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>. <year>2014</year>;<volume>307</volume>:<fpage>G760</fpage>&#x02010;<lpage>G768</lpage>.<pub-id pub-id-type="pmid">25104497</pub-id></mixed-citation></ref><ref id="dom12899-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dom12899-cit-0017">
<string-name>
<surname>Ramage</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Akyol</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fletcher</surname>
<given-names>AM</given-names>
</string-name>, et al. <article-title>Glucocorticoids acutely increase brown adipose tissue activity in humans, revealing species&#x02010;specific differences in UCP&#x02010;1 regulation</article-title>. <source>Cell Metab</source>. <year>2016</year>;<volume>24</volume>:<fpage>130</fpage>&#x02010;<lpage>141</lpage>.<pub-id pub-id-type="pmid">27411014</pub-id></mixed-citation></ref><ref id="dom12899-bib-0018"><label>18</label><mixed-citation publication-type="book" id="dom12899-cit-0018">
<string-name>
<surname>Wolfe</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Chinkes</surname>
<given-names>DL</given-names>
</string-name>. <source>Isotope Tracers in Metabolic Research. Principles and Practice of Kinetic Analysis</source>. <publisher-loc>Hoboken, NJ</publisher-loc>: <publisher-name>John Wiley and Sons Inc.</publisher-name>; <year>2005</year>.</mixed-citation></ref><ref id="dom12899-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dom12899-cit-0019">
<string-name>
<surname>Romijn</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Coyle</surname>
<given-names>EF</given-names>
</string-name>, <string-name>
<surname>Sidossis</surname>
<given-names>LS</given-names>
</string-name>, et al. <article-title>Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration</article-title>. <source>Am J Physiol</source>. <year>1993</year>;<volume>265</volume>:<fpage>E380</fpage>&#x02010;<lpage>E391</lpage>.<pub-id pub-id-type="pmid">8214047</pub-id></mixed-citation></ref><ref id="dom12899-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dom12899-cit-0020">
<string-name>
<surname>Simpson</surname>
<given-names>HL</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>
<given-names>NC</given-names>
</string-name>, <string-name>
<surname>Shojaee&#x02010;Moradie</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Insulin&#x02010;like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2004</year>;<volume>89</volume>:<fpage>425</fpage>&#x02010;<lpage>432</lpage>.<pub-id pub-id-type="pmid">14715881</pub-id></mixed-citation></ref><ref id="dom12899-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="dom12899-cit-0021">
<string-name>
<surname>Berkin</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Inglis</surname>
<given-names>GC</given-names>
</string-name>, <string-name>
<surname>Ball</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Thomson</surname>
<given-names>NC</given-names>
</string-name>. <article-title>Circulating adrenaline and noradrenaline concentrations during exercise in patients with exercise induced asthma and normal subjects</article-title>. <source>Thorax</source>. <year>1988</year>;<volume>43</volume>:<fpage>295</fpage>&#x02010;<lpage>299</lpage>.<pub-id pub-id-type="pmid">3406917</pub-id></mixed-citation></ref><ref id="dom12899-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="dom12899-cit-0022">
<string-name>
<surname>Hughes</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Reynolds</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Andrew</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Critchley</surname>
<given-names>HO</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>BR</given-names>
</string-name>. <article-title>Glucocorticoids turn over slowly in human adipose tissue in vivo</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2010</year>;<volume>95</volume>:<fpage>4696</fpage>&#x02010;<lpage>4702</lpage>.<pub-id pub-id-type="pmid">20631029</pub-id></mixed-citation></ref><ref id="dom12899-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="dom12899-cit-0023">
<string-name>
<surname>Campbell</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Peckett</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>D'souza</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Hawke</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Riddell</surname>
<given-names>MC</given-names>
</string-name>. <article-title>Adipogenic and lipolytic effects of chronic glucocorticoid exposure</article-title>. <source>Am J Physiol Cell Physiol</source>. <year>2011</year>;<volume>300</volume>:<fpage>C198</fpage>&#x02010;<lpage>C209</lpage>.<pub-id pub-id-type="pmid">20943959</pub-id></mixed-citation></ref><ref id="dom12899-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="dom12899-cit-0024">
<string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Deng</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>PEDF expression is inhibited by insulin treatment in adipose tissue via suppressing 11beta&#x02010;HSD1</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>:<fpage>e84016</fpage>.<pub-id pub-id-type="pmid">24367624</pub-id></mixed-citation></ref><ref id="dom12899-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="dom12899-cit-0025">
<string-name>
<surname>Koliwad</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Kuo</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Shipp</surname>
<given-names>LE</given-names>
</string-name>, et al. <article-title>Angiopoietin&#x02010;like 4 (ANGPTL4, fasting&#x02010;induced adipose factor) is a direct glucocorticoid receptor target and participates in glucocorticoid&#x02010;regulated triglyceride metabolism</article-title>. <source>J Biol Chem</source>. <year>2009</year>;<volume>284</volume>:<fpage>25593</fpage>&#x02010;<lpage>25601</lpage>.<pub-id pub-id-type="pmid">19628874</pub-id></mixed-citation></ref><ref id="dom12899-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="dom12899-cit-0026">
<string-name>
<surname>Nakada</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Stadel</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Poksay</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Crooke</surname>
<given-names>ST</given-names>
</string-name>. <article-title>Glucocorticoid regulation of beta&#x02010;adrenergic receptors in 3T3&#x02010;L1 preadipocytes</article-title>. <source>Mol Pharmacol</source>. <year>1987</year>;<volume>31</volume>:<fpage>377</fpage>&#x02010;<lpage>384</lpage>.<pub-id pub-id-type="pmid">3033466</pub-id></mixed-citation></ref><ref id="dom12899-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="dom12899-cit-0027">
<string-name>
<surname>Lacasa</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Agli</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Giudicelli</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Permissive action of glucocorticoids on catecholamine&#x02010;induced lipolysis: direct &#x0201c;in vitro&#x0201d; effects on the fat cell beta&#x02010;adrenoreceptor&#x02010;coupled&#x02010;adenylate cyclase system</article-title>. <source>Biochem Biophys Res Commun</source>. <year>1988</year>;<volume>153</volume>:<fpage>489</fpage>&#x02010;<lpage>497</lpage>.<pub-id pub-id-type="pmid">2838019</pub-id></mixed-citation></ref><ref id="dom12899-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="dom12899-cit-0028">
<string-name>
<surname>Yip</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Goodman</surname>
<given-names>HM</given-names>
</string-name>. <article-title>Growth hormone and dexamethasone stimulate lipolysis and activate adenylyl cyclase in rat adipocytes by selectively shifting Gi alpha2 to lower density membrane fractions</article-title>. <source>Endocrinology</source>. <year>1999</year>;<volume>140</volume>:<fpage>1219</fpage>&#x02010;<lpage>1227</lpage>.<pub-id pub-id-type="pmid">10067847</pub-id></mixed-citation></ref><ref id="dom12899-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="dom12899-cit-0029">
<string-name>
<surname>Yang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Lombes</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase</article-title>. <source>Cell Metab</source>. <year>2010</year>;<volume>11</volume>:<fpage>194</fpage>&#x02010;<lpage>205</lpage>.<pub-id pub-id-type="pmid">20197052</pub-id></mixed-citation></ref><ref id="dom12899-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="dom12899-cit-0030">
<string-name>
<surname>Chau</surname>
<given-names>YY</given-names>
</string-name>, <string-name>
<surname>Bandiera</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Serrels</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Visceral and subcutaneous fat have different origins and evidence supports a mesothelial source</article-title>. <source>Nat Cell Biol</source>. <year>2014</year>;<volume>16</volume>:<fpage>367</fpage>&#x02010;<lpage>375</lpage>.<pub-id pub-id-type="pmid">24609269</pub-id></mixed-citation></ref><ref id="dom12899-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="dom12899-cit-0031">
<string-name>
<surname>Nielsen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Hensrud</surname>
<given-names>DD</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>MD</given-names>
</string-name>. <article-title>Splanchnic lipolysis in human obesity</article-title>. <source>J Clin Invest</source>. <year>2004</year>;<volume>113</volume>:<fpage>1582</fpage>&#x02010;<lpage>1588</lpage>.<pub-id pub-id-type="pmid">15173884</pub-id></mixed-citation></ref><ref id="dom12899-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="dom12899-cit-0032">
<string-name>
<surname>Saunders</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Sonksen</surname>
<given-names>PH</given-names>
</string-name>. <article-title>Glucose and free fatty acid turnover in Cushing's syndrome</article-title>. <source>J Endocrinol Invest</source>. <year>1980</year>;<volume>3</volume>:<fpage>309</fpage>&#x02010;<lpage>311</lpage>.<pub-id pub-id-type="pmid">7430558</pub-id></mixed-citation></ref><ref id="dom12899-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="dom12899-cit-0033">
<string-name>
<surname>Birkenhager</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Timmermans</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Lamberts</surname>
<given-names>SW</given-names>
</string-name>. <article-title>Depressed plasma FFA turnover rate in Cushing's syndrome</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1976</year>;<volume>42</volume>:<fpage>28</fpage>&#x02010;<lpage>32</lpage>.<pub-id pub-id-type="pmid">1249192</pub-id></mixed-citation></ref><ref id="dom12899-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="dom12899-cit-0034">
<string-name>
<surname>Stavreva</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Wiench</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>John</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Ultradian hormone stimulation induces glucocorticoid receptor&#x02010;mediated pulses of gene transcription</article-title>. <source>Nat Cell Biol</source>. <year>2009</year>;<volume>11</volume>:<fpage>1093</fpage>&#x02010;<lpage>1102</lpage>.<pub-id pub-id-type="pmid">19684579</pub-id></mixed-citation></ref></ref-list></back></article>